Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers [Original Articles]

Conclusions:
PA requirements for PCSK9is are greater than for selected other drugs within the cardiometabolic disease area, raising concerns about whether payer policies to discourage inappropriate use may also be restricting access to these drugs in patients who need them.

Source: Circulation: Cardiovascular Quality and Outcomes - January 11, 2018 Category: Cardiology Authors: Doshi, J. A., Puckett, J. T., Parmacek, M. S., Rader, D. J. Tags: Ethics and Policy, Health Services Original Articles Source Type: research